A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
28 Sep 2026 · 03:42 CST Terminal Access 终端入口 →
600535.SH上海证券交易所 · 主板 Main

Tasly 天士力

Traditional Chinese Medicine 中药Ⅱ
¥13.68−¥0.21 · −1.51%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥13.88
High 最高
¥13.90
Low 最低
¥13.64
Prev Close 昨收
¥13.89
Volume 成交量
1,048.4万股
Turnover 成交额
¥1.44亿
Mkt Cap 总市值
¥204亿
P/E 市盈率
16.7×
Recent Activity 近期动态All Filings 全部公告 →

One significant filing since 31 May 2026, on earnings pre-announcement (15 Jul 2026): 天士力2026年半年度业绩快报.
自 31 May 2026 起有一份重大公告(earnings pre-announcement,15 Jul 2026):天士力2026年半年度业绩快报。

Price History 价格走势

66 trading days 个交易日 · High 最高 ¥16.12 · Low 最低 ¥13.23
13.5014.0014.5015.0015.5016.00
Volume 成交量
5,141.7万
25 Jun17 Jul10 Aug02 Sep24 Sep

Against Its Own History 与自身历史比较

16.7×
Median 中值 21.4× · Range 区间 10.1× to 40.5× · 19 periods 期
1.56×
Median 中值 1.81× · Range 区间 1.20× to 2.06× · 20 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥13.23¥0.8216.1×¥8.751.51×
31 Mar 2026 一季报¥14.35¥0.7818.5×¥8.551.68×
31 Dec 2025 年报¥15.07¥0.7420.4×¥8.301.82×
30 Sep 2025 三季报¥15.80¥0.7421.4×¥8.241.92×
30 Jun 2025 中报¥15.65¥0.7221.7×¥8.291.89×
31 Mar 2025 一季报¥15.11¥0.6523.1×¥7.981.89×
31 Dec 2024 年报¥14.46¥0.6422.6×¥7.971.81×
30 Sep 2024 三季报¥16.15¥0.5927.4×¥8.511.90×
30 Jun 2024 中报¥12.58¥0.6918.2×¥8.391.50×
31 Mar 2024 一季报¥16.11¥0.7421.8×¥8.471.90×
31 Dec 2023 年报¥17.02¥0.7223.6×¥8.252.06×
30 Sep 2023 三季报¥14.52¥0.7419.6×¥8.271.76×
30 Jun 2023 中报¥14.51¥0.5725.5×¥8.121.79×
31 Mar 2023 一季报¥15.05¥0.3740.5×¥8.371.80×
31 Dec 2022 年报¥10.76−¥0.18—¥8.271.30×
30 Sep 2022 三季报¥9.76¥0.3527.9×¥8.141.20×
30 Jun 2022 中报¥10.51¥0.6216.8×¥8.021.31×
31 Mar 2022 一季报¥15.31¥0.9815.6×¥8.221.86×
31 Dec 2021 年报¥15.85¥1.5710.1×¥8.581.85×
30 Sep 2021 三季报¥13.30¥1.0113.2×¥8.541.56×

Consensus Forward EPS 机构预测每股收益

Fiscal Year 年度EPS Median 中值Range 区间Brokers 机构数Forward P/E 预测市盈率
2026¥0.86¥0.83 to ¥0.90215.8×
2027¥0.93¥0.90 to ¥0.96214.7×
2028¥1.10¥1.10 to ¥1.11212.4×
Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA